• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by PLUS THERAPEUTICS Inc.

    6/18/26 4:30:29 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care
    Get the next $PSTV alert in real time by email
    S-8 1 pstv-20260618.htm S-8 S-8

    As filed with the Securities and Exchange Commission on June 18, 2026

    Registration No. 333-   

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    PLUS THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

    Delaware

    33-0827593

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

     

    6420 Levit Green Boulevard

    Suite 310

    Houston, Texas

    77021

    (Address of Principal Executive Offices)

    (Zip Code)

    Sixth Amended and Restated Plus Therapeutics, Inc. 2020 Stock Incentive Plan

    Plus Therapeutics, Inc. 2015 New Employee Incentive Plan

    (Full title of the Plans)

    Marc H. Hedrick, M.D.

    President and Chief Executive Officer

    Plus Therapeutics, Inc.

    6420 Levit Green Boulevard

    Suite 310

    Houston, Texas 77021

    (737) 255-7194

    (Name, address and telephone number of agent for service)

    With copies to:

    David E. Danovitch

    Charles E. Chambers, Jr.

    Sullivan & Worcester LLP

    1251 Avenue of the Americas

    New York, New York 10020

    (212) 660-3060

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 under the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.


    EXPLANATORY NOTE

    This registration statement (this “Registration Statement”) registers an aggregate of 860,000 additional shares of common stock, par value $0.001 per share (the “Common Stock”), of Plus Therapeutics, Inc. (the “Registrant”), consisting of (i) 740,000 shares of Common Stock issuable pursuant to the Sixth Amended and Restated Plus Therapeutics, Inc. 2020 Stock Incentive Plan (the “2020 Plan”), representing an increase of 740,000 shares of Common Stock reserved for issuance under the 2020 Plan, as a result of an amendment thereto, which was adopted by the board of directors (the “Board”) of the Registrant on March 31, 2026 and approved by the Registrant’s stockholders at the Annual Meeting of Stockholders held on May 14, 2026; and (ii) 120,000 shares of Common Stock issuable pursuant to the Plus Therapeutics, Inc. 2015 New Employee Incentive Plan (as amended, the “2015 Plan”), representing an increase of 120,000 shares of Common Stock reserved for issuance under the 2015 Plan as a result of an amendment thereto, which was adopted by the Board on November 7, 2025. Pursuant to General Instruction E to Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”), the contents of the Registrant’s registration statements on Form S-8 filed with the U.S. Securities and Exchange Commission (the “Commission”) on March 15, 2016 (Registration No. 333-210211), March 9, 2018 (Registration No. 333-223566), June 30, 2020 (Registration No. 333-239548), August 23, 2024 (Registration No. 333-281758), and August 22, 2025 (Registration No. 333-289822) are incorporated by reference and made part of this Registration Statement. Any items in such registration statements not expressly changed hereby shall be as set forth in such registration statements.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents filed by Registrant with the Commission are hereby incorporated by reference in this Registration Statement:

    (a)

     

    the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025 (filed with the Commission on March 12, 2026);

    (b)

     

    all other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) since the end of the fiscal year covered by the document referred to in (a) above (other than the portions of those documents not deemed to be filed); and

    (c)

     

    the description of the Registrant’s Common Stock contained in Exhibit 4.1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on March 12, 2026 (File No. 001-34375).

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of the filing of such documents.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


     

     

    Item 8. Exhibits.

     

     

     

     

     

    Incorporated by Reference

    Exhibit Number

    Description

    Filed
    Herewith

    Form

    File Number

    Exhibit

    Filing Date

    4.1

    Sixth Amended and Restated Plus Therapeutics, Inc. 2020 Stock Incentive Plan

     

    Schedule 14A

    001-34375

    Appendix A

    03/31/2026

     

     

     

     

     

     

     

    4.2

    Amended and Restated Plus Therapeutics, Inc. 2015 New Employee Incentive Plan, dated November 7, 2025

     

    S-1

    333-292637

    10.9

    01/09/2026

     

     

     

     

     

     

     

    5.1

    Opinion of Sullivan & Worcester LLP

    X

     

     

     

     

     

     

     

     

     

     

     

    23.1

    Opinion of Sullivan & Worcester LLP (included in Exhibit 5.1)

    X

     

     

     

     

     

     

     

     

     

     

     

    23.2

    Consent of CBIZ CPAs, P.C., Independent Registered Public Accounting Firm

    X

     

     

     

     

     

     

     

     

     

     

     

    23.3

    Consent of BDO USA, P.C., Independent Registered Public Accounting Firm

    X

     

     

     

     

     

     

     

     

     

     

     

    24.1

    Power of Attorney (included on the signature page to this Registration Statement)

    X

     

     

     

     

     

     

     

     

     

     

     

    99.1

    Form of Stock Unit Agreement under the 2020 Stock Incentive Plan

     

    S-8

    333-289822

    99.2

    08/22/2025

     

     

     

     

     

     

     

    99.2

    Form of Notice of Grant and Stock Option Agreement under the 2020 Stock Incentive Plan

     

    10-K

    001-34375

    10.26

    02/24/2022

     

     

     

     

     

     

     

    107

    Filing Fee Table

    X

     

     

     

     


     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Houston, Texas, on June 18, 2026.

    PLUS THERAPEUTICS, INC.

     

     

    By:

    /s/ Marc H. Hedrick, M.D.

     

    Name:

    Marc H. Hedrick, M.D.

     

    Title:

    President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Marc H. Hedrick, M.D. and Andrew Sims, and each of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and revocation, in his or her name and on his or her behalf, to do any and all acts and things and execute, in the name of the undersigned, any and all instruments which said attorney-in-fact and agent may deem necessary or advisable to enable the Registrant to comply with the Securities Act, and any rules, regulations, or requirements of the Commission in respect thereof, in connection with the filing with the Commission of this Registration Statement under the Securities Act, including specifically but without limitation, power and authority to sign the name of the undersigned to such Registration Statement, and any amendments to such Registration Statement (including post-effective amendments), and to file the same with all exhibits thereto and other documents in connection therewith, with the Commission and any applicable securities exchange or securities regulatory body, to sign any and all applications, registration statements, notices or other documents necessary or advisable to comply with applicable securities laws, including without limitation state securities laws, and to file the same, together with other documents in connection therewith with the appropriate authorities, including without limitation state securities authorities, granting unto said attorney-in-fact and agent, full power and authority to do and to perform each and every act and thing requisite or necessary to be done in and about the premises, as fully and to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof. This Power of Attorney may be signed in several counterparts.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities set forth below on June 18, 2026.

     

    Signature

     

    Title

     

    Date

    /s/ Marc H. Hedrick, M.D.

     

    President, Chief Executive Officer and Director
    (Principal Executive Officer)

     

    June 18, 2026

    Marc H. Hedrick, M.D.

     

     

     

     

     

     

     

    /s/ Andrew Sims

     

    Chief Financial Officer
    (Principal Financial and Accounting Officer)

     

    June 18, 2026

    Andrew Sims

     

     

     

     

     

     

     

    /s/ Richard J. Hawkins

     

    Chair of the Board of Directors

     

    June 18, 2026

    Richard J. Hawkins

     

     

     

     

     

     

     

    /s/ Howard Clowes

     

    Director

     

    June 18, 2026

    Howard Clowes

     

     

     

     

     

     

     

    /s/ An Van Es-Johansson, M.D.

     

    Director

     

    June 18, 2026

    An Van Es-Johansson, M.D.

     

     

     

     

     

     

     

    /s/ Ronald A. Andrews

     

    Director

     

    June 18, 2026

    Ronald A. Andrews

     

     

     

     

     

     

     

    /s/ Kyle Guse

     

    Director

     

    June 18, 2026

    Kyle Guse

     

     

     


    Get the next $PSTV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PSTV

    DatePrice TargetRatingAnalyst
    2/3/2026$2.00Buy
    Lake Street
    9/3/2025$5.00Hold → Buy
    D. Boral Capital
    3/17/2025$9.00Buy
    D. Boral Capital
    More analyst ratings

    $PSTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Van Es-Johansson An

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    5/18/26 4:13:37 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Hawkins Richard J

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    5/18/26 4:12:10 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Guse Kyle

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    5/18/26 4:11:53 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Plus Therapeutics to Provide Business Update Call on June 30, 2026

    HOUSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company focused on central nervous system ("CNS") cancers, today announced that management will host a business update conference call and webcast on Tuesday, June 30, 2026, at 8:30 a.m. Eastern Time. During the call, management will focus on the Company’s CNSide® diagnostic launch and its integrated development plan for lead drug Reyobiq. Furthermore, management will provide further detail on its CNS oncology strategy and native artificial intelligence development plans. "Our team is making substantial progress in all 3 areas of the company, specifically diagnostics,

    6/23/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory

    HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company advancing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that its Houston-based clinical laboratory has received accreditation from the College of American Pathologists (CAP) following a recent on-site inspection conducted under the CAP Laboratory Accreditation Program. The CAP Laboratory Accreditation Program is internationally recognized as the "gold standard" in laboratory accreditation. As part of this distinction, CNSide Diagnostics' laboratory un

    6/4/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

    Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making reducing healthcare costs by 40% Presentation receives blue-ribbon recognition at the ISPOR Annual Meeting, the premier global gathering for health economics and outcomes research HOUSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of LM using the CNSide ce

    5/26/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    SEC Filings

    View All

    SEC Form S-8 filed by PLUS THERAPEUTICS Inc.

    S-8 - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    6/18/26 4:30:29 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by PLUS THERAPEUTICS Inc.

    EFFECT - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    6/8/26 12:15:32 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    6/5/26 4:30:16 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sims Andrew John Hugh Macintyre bought $10,200 worth of shares (20,000 units at $0.51), increasing direct ownership by 42% to 68,138 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    11/5/25 8:30:03 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Director Lenk Robert P bought $53,779 worth of shares (110,000 units at $0.49), increasing direct ownership by 375% to 139,327 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    8/25/25 7:30:05 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Director Hawkins Richard J bought $5,996 worth of shares (4,000 units at $1.50), increasing direct ownership by 36% to 15,188 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    9/17/24 7:00:04 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Plus Therapeutics with a new price target

    Lake Street initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $2.00

    2/3/26 8:52:26 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics upgraded by D. Boral Capital with a new price target

    D. Boral Capital upgraded Plus Therapeutics from Hold to Buy and set a new price target of $5.00

    9/3/25 8:18:22 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    D. Boral Capital initiated coverage on Plus Therapeutics with a new price target

    D. Boral Capital initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $9.00

    3/17/25 7:41:57 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Leadership Updates

    Live Leadership Updates

    View All

    Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    HOUSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that it has granted inducement awards to Eric J Daniels, M.D., its new Chief Development Officer who joined the Company on April 20, 2026. The awards were granted on April 20, 2026 under the Company's 2015 New Employee Incentive Plan, as amended, which provides for the granting of equity awards to new employees as an inducement to join the Company. The inducement awards consist of options to purchase 20,000 shares of the Company common

    4/22/26 4:30:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

    HOUSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the appointment of Randy H. Goodman, Ph.D., M.H.A., as Vice President, Value Strategy & Health Economics and Outcomes Research (HEOR), effective April 13th, 2026. Dr. Goodman is a highly experienced health economics and market access leader with more than 20 years of experience spanning global pricing and reimbursement strategy, real-world evidence generation, and value-based healthcare modeling across the biotechnology, pharmaceutic

    4/15/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline

    HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the appointment of Eric J. Daniels, M.D., MBA, as Chief Development Officer, effective April 20, 2026. Dr. Daniels is a seasoned biotechnology executive with more than two decades of experience spanning clinical development, regulatory strategy, corporate operations, and business development. He most recently served as Chief Development Officer at Kiora Pharmaceuticals , where he oversaw the company's full development portfolio

    4/9/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Financials

    Live finance-specific insights

    View All

    Plus Therapeutics to Provide Business Update Call on June 30, 2026

    HOUSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company focused on central nervous system ("CNS") cancers, today announced that management will host a business update conference call and webcast on Tuesday, June 30, 2026, at 8:30 a.m. Eastern Time. During the call, management will focus on the Company’s CNSide® diagnostic launch and its integrated development plan for lead drug Reyobiq. Furthermore, management will provide further detail on its CNS oncology strategy and native artificial intelligence development plans. "Our team is making substantial progress in all 3 areas of the company, specifically diagnostics,

    6/23/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

    HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announced today the initiation of manufacturing activities and technology transfer with SpectronRx under a previously executed Master Services Agreement (MSA), in support of late-stage clinical manufacturing of Rhenium-186 and REYOBIQ. With SpectronRx serving as a second GMP manufacturing site alongside Radiomedix, and Rhenium-186 isotope supplied through Telix Pharmaceuticals, Plus strengthens the reliability of its multi-partner supply chain

    4/23/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

    HOUSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that the American Medical Association (AMA) has approved a new, Proprietary Laboratory Analyses (PLA) Current Procedural Terminology (CPT) code for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) test. The dedicated billing code, 0640U, effective July 1, 2026, establishes a unique reimbursement identifier for the CNSide CSF TCE test, supporting payer claims processing and facilitating broader clinical adoptio

    4/7/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PLUS THERAPEUTICS Inc.

    SC 13G - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

    6/5/24 7:26:01 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

    SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

    2/13/23 3:25:03 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

    SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

    2/11/22 7:53:23 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care